Dutasteride

Drug Profile

Dutasteride

Alternative Names: Avodart; Avolve; GG 745; GI 198745

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiandrogens; Azasteroids; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Preregistration Submission Withdrawal Prostate cancer; Prostatic intraepithelial neoplasia
  • No development reported Alopecia

Most Recent Events

  • 25 Jan 2018 No development reported - Phase-III for Alopecia in Singapore, Chile, Taiwan, Hong Kong, Japan, South Korea (PO)
  • 03 Mar 2017 GlaxoSmithKline completes a phase III trial in Benign prostatic hyperplasia (Combination therapy) in China, Japan, South Korea and Taiwan (NCT02058368)
  • 31 Mar 2016 GlaxoSmithKline completes a phase III trial for Male sexual dysfunction (in patients with androgenetic alopecia) in Chile, Hong Kong, Singapore, Taiwan and South Korea(NCT02014584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top